Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
With
AbbVie (prior sponsor, Abbott)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia
Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (\</=) 1
Adequate bone marrow function
Adequate coagulation, renal and hepatic function
For all participants, agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (\<) 1% per year during the treatment period and for at least 90 days (30 days for women) after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer
You may not be if
Participants who have undergone allogenic stem cell transplant are ineligible unless they meet the following criteria, a) participants who are off all immunosuppressive therapy, b) participants who have no signs and/or symptoms of acute or chronic graft versus host disease, or c) participants must have appropriate hematology counts
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Investigational or anti-cancer therapy within 5 half-lives prior to the first dose of study drug
History of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease
